The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -24,480,848 |
| Amortization of debt discount | 8,019,448 |
| Initial recognition of forward purchase agreement liability | -95,062 |
| Issuance of commitment shares under eloc agreement | -275,000 |
| Loss on extinguishment of debt | -364,109 |
| Change in fair value of derivative liabilities and convertible notes | 3,860,889 |
| Stock-based compensation | 14,131,250 |
| Prepaid expenses and other current assets | -174,254 |
| Inventories | 253,160 |
| Accounts payable | -323,776 |
| Accrued expenses | 1,047,088 |
| Other current liabilities | -111,026 |
| Net cash flows used in operating activities | -4,923,488 |
| Proceeds from recapitalization | 265,827 |
| Proceeds from issuance of convertible notes | 10,250,000 |
| Repayment of convertible notes | 3,032,645 |
| Transaction costs paid in connection with convertible notes | 907,499 |
| Proceeds from notes payable - related party | 50,000 |
| Repayment of notes payable related party | 701,924 |
| Net cash flows provided by financing activities | 5,923,759 |
| Net change in cash | 1,000,271 |
| Cash, beginning of the year | 3,633 |
| Cash, end of the year | 1,003,904 |
Aspire Biopharma Holdings, Inc. (ASBPW)
Aspire Biopharma Holdings, Inc. (ASBPW)